Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001641172-25-024017
Filing Date
2025-08-14
Accepted
2025-08-14 16:05:22
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5842
  Complete submission text file 0001641172-25-024017.txt   7523
Mailing Address 150 EAST 58TH STREET 14TH FLOOR NEW YORK NY 10155
Business Address 150 EAST 58TH STREET 14TH FLOOR NEW YORK NY 10155 212-446-2466
TYNDALL CAPITAL PARTNERS L P (Filed by) CIK: 0001219314 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 301 BINNEY STREET CAMBRIDGE MA 02142
Business Address 301 BINNEY STREET CAMBRIDGE MA 02142 617-621-7722
Cyclerion Therapeutics, Inc. (Subject) CIK: 0001755237 (see all company filings)

EIN.: 831895370 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90979 | Film No.: 251218779
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)